Radiopharm Theranostics Ltd (RADX) Form 6-K — Oct 30, 2026
Radiopharm Theranostics reported its September 2026 quarterly results, anchored by a successful FDA End-of-Phase 2 meeting clearing RAD101 for a pivotal Phase 3 imaging trial in recurrent brain metastases, expected to start in 1Q27 with Siemens Healthineers supporting U.S. dose supply. The pipeline advanced on multiple fronts: RAD301 posted positive Phase 1 imaging data in pancreatic cancer, RAD202 progressed to a fourth 180mCi dosing cohort in the HEAT trial, and RV-01 dosed its first patient in cohort two of its first-in-human study.
Key figures
- Revenue
- 0
- Net Income
- 0
- Cash Position
- A$7.5 million (A$7,462k) at quarter end, up from A$4.1 million prior quarter
- Rd tax refund fy2025
- A$5,885,131 (incl. A$104,475 interest)
- Atm facility available
- US$18.9 million (established December 2025)
- Rd advance rockford capital
- US$8,000,000 post-quarter, secured against FY26 RDTI
- Estimated quarters of funding
- 0.7
- Radiopharm ventures ownership
- increased from 87.5% to 93.75%
- Share purchase plan completed
- A$3 million
- Net operating cash outflow qtr
- A$10.7 million (A$10,687k)
- Rad101 phase2b mri concordance
- 93% across all evaluable lesions
- Institutional placement completed
- A$12.5 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.